Full Press Release Details
CORAL GABLES, Fla., Nov. 07, 2025 (GLOBE NEWSWIRE) --Relmada Therapeutics, Inc.(Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system indications, today announced plans to host a conference call and webcast on Thursday, November 13, 2025 at 4:30 PM ET to discuss financial results for the third quarter ended September 30, 2025 and recent business progress.
Conference Call and Webcast Information:
A replay of the webcast will be available in the Investors section of the Relmada website athttps://www.relmada.com/investors/ir-calendar.
About Relmada Therapeutics, Inc.Relmada Therapeutics is a clinical-stage biotechnology company focused on developing transformative therapies for oncology and central nervous system conditions. Its lead candidates, NDV-01 and sepranolone, are advancing through mid-stage clinical development with the potential to address significant unmet needs.
For more information, visitwww.relmada.com